Marginal zone B-cell lymphoma (MZL) is the second most common subtype of non-Hodgkin's lymphoma in Korea (17.3%).Method
We focus on non-gastric MZL studies conducted in Korea that highlight the most recent advances with respect to MZL clinical characteristics, natural history, treatment outcomes, and prognostic factors. Results: In a cohort of Korean patients with NG-MZL, the overall male-to-female ratio was almost 1:1. The median age of the cohort was 49 years. In these patients, the principal clinical features were limited stage, small tumor burden, excellent performance status, and normal LDH. However, patients with extranodal MZL and those with nodal MZL show differences in clinical presentation. In retrospective study, of the 151 patients with stage I or II disease, 138 (91.4%) were treated with local modalities, such as radiation therapy or surgery. The 5-year PFS and OS rates were 74.7% and 95.9%, respectively. In advanced stage patients treated with R-CVP chemotherapy, 24 patients achieved CR (60%), 11 had PR (27.5%), the estimated 3-year PFS and OS rates were 59.5% and 95.0%. In a retrospective multivariate analysis of the Korean data, nodal MZL and advanced stage were predictive of the PFS in a multivariate analysis.Conclusion
In planning future clinical trials of MZL, at least two systems must first be established and implemented. The first of these is a well-organized study group. The second prerequisite is cooperation among clinical departments, such as those in pathology, radiation oncology, ophthalmology, and gastroenterology. Regarding the Korean lymphoma study, if the past 5 years are collectively referred to as the ‘age of retrospective data collection’, the near future will be referred to as the ‘age of prospective and international clinical trials and translational studies’.